Capricor Therapeutics (CAPR) Common Equity (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Common Equity of $278.7 million for Q1 2026, up 118.34% year-over-year from $127.6 million in Q1 2025, and down 8.86% quarter-over-quarter from $305.8 million in Q4 2025.
Capricor Therapeutics (CAPR) Common Equity (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $278.7 million for Q1 2026.
- In Q1 2026, Common Equity rose 118.34% year-over-year to $278.7 million; the TTM figure through Mar 2026 stood at $278.7 million (up 118.34% YoY), while the FY2025 annual figure was $305.8 million, up 110.22% from the prior year.
- Common Equity for Q1 2026 stood at $278.7 million, down from $305.8 million in the prior quarter.
- The five-year high for Common Equity was $305.8 million in Q4 2025, with the low at -$1.8 million in Q3 2023.
- The 5-year median for Common Equity is $22.6 million (2023), against an average of $73.2 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 111.59% in 2023, then jumped 3918.69% in 2024.
- Capricor Therapeutics' Common Equity stood at $11.8 million in 2022, then jumped by 91.76% to $22.6 million in 2023, then jumped by 543.6% to $145.5 million in 2024, then surged by 110.22% to $305.8 million in 2025, then dropped by 8.86% to $278.7 million in 2026.
- Business Quant data shows CAPR's Common Equity at $278.7 million in Q1 2026, $305.8 million in Q4 2025, and $83.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 278.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278.70 Mn |
| Dec 31, 2025 | 305.79 Mn |
| Sep 30, 2025 | 83.87 Mn |
| Jun 30, 2025 | 104.98 Mn |
| Mar 31, 2025 | 127.65 Mn |
| Dec 31, 2024 | 145.46 Mn |
| Sep 30, 2024 | 68.26 Mn |
| Jun 30, 2024 | 11.50 Mn |
| Mar 31, 2024 | 18.43 Mn |
| Dec 31, 2023 | 22.60 Mn |
| Sep 30, 2023 | -1.79 Mn |
| Jun 30, 2023 | 2.73 Mn |
| Mar 31, 2023 | 6.21 Mn |
| Dec 31, 2022 | 11.79 Mn |
| Sep 30, 2022 | 15.43 Mn |
| Jun 30, 2022 | 18.73 Mn |
| Mar 31, 2022 | 24.64 Mn |
| Dec 31, 2021 | 31.37 Mn |
| Sep 30, 2021 | 36.74 Mn |
| Jun 30, 2021 | 33.38 Mn |